testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone]

What the CMS Formulary Data Shows for testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone]

Per the CMS 2026 Part D formulary file, testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone] (RxNorm concept RXCUI 835842, generic name testosterone cypionate) appears on 105 distinct formulary files spanning 1,340 Medicare Part D plan offerings - 26.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.4.

Real-world access to testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone] depends on utilization management as much as tier placement: 83.8% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 242,810 Part D beneficiaries filled testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone] in 2023, with total plan-and-beneficiary spending of $37,968,692 and an average per-beneficiary annual cost of $156.37. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry testosterone cypionate 200 MG/ML Injectable Solution [Depo-testosterone] today.